

IndEx animal model


Inducible System for *in vivo* target validation

TECHNOLOGY

IndEx animal model

Models for *in vivo* target validation are restricted in usability by long time lines and/or financial limitations. In addition the inhibition rates are often disappointing as the accessibility *in vivo* is very limited. We change the model by genetically modifying the cells outside the body and transplant it into the animals. With the IndEx model we thereby circumvent any delivery problems and shorten the time line down to 3-4 months. By using a Doxycycline (Dox) inducible system the gene of interest can be silenced whenever desired.

Scheme of IndEx animal model for silencing of an oncogene



- High prognostic value:** Inducibility of gene silencing matches pharmacological situation
- High rates of *in vivo* gene silencing:** *Ex vivo* genetic modifications allow excellent knock down rates
- Fast results:** no breeding or antibody screens necessary

Trust the experts: SIRION BIOTECH creates the genetically modified cells and vivoPharm conducts the tailored animal studies.

IN COOPERATION

SIRION BIOTECH

Am Klopferspitz 19
82152 Martinsried
GERMANY
P.: 0049 (0) 89 700 961 999
F.: 0049 (0) 89 700 961 998
Email: info@sirion-biotech.de
www.sirion-biotech.de

VIVOPHARM

Phone: +49 89 552797590
Fax: +49 89 552797599
Email Sales:
sales@vivopharm.eu
vivoPharm Europe Limited
Grillparzerstrasse 25
81675 Munich
GERMANY

Delivering RNAi to cells